POMx alleviates disease activity and improves some blood biomarkers of inflammation and oxidative stress in RA patients.

Background:Rheumatoid arthritis is a symmetric peripheral polyarthritis of unknown etiology that, untreated or if unresponsive the therapy, typically leads to deformity and destruction of joints due to erosion of cartilage and bone. Omega-3 fatty acids have been shown to reduce morning stiffness, the number of tender joints and swollen joints in patients with rheumatoid arthritis. This study is designed for evaluation of omega-3 effects on disease activity and remission of rheumatoid arthritis in DMARDs treated patients and on weight changes and reduction of analgesic drugs consumption versus placebo.Methods:Sixty patients with active rheumatoid arthritis (49 female and 11 male) underwent rheumatologist examination and disease activity score were calculated. Then patients were enrolled in this 12 week, double blind, randomized, placebo- controlled study. The patients in both groups continued their pre study standard treatment. The patients were visited every 4 weeks, 4 times and data were recorded.Results:Significant improvement in the patient’s global evaluation and in the physician’s assessment of disease was observed in those taking omega-3. The proportions of patients who improved and of those who were able to reduce their concomitant analgesic medication were significantly greater with omega-3 consumption. There were no weight changes.Conclusion:Daily supplementation with omega-3 results has significant clinical benefit and may reduce the need for concomitant analgesic consumption without weight changes.

According to the findings of this clinical trial, PJ consumption can improve physical function and stiffness, decrease breakdown cartilage enzymes and increase antioxidant status in patients with knee OA. © 2016 Society of Chemical Industry.

Sesamin exhibited a protective effect on cardiovascular risk factors in patients with RA. However, further investigation is suggested.

Aim The purpose of the present study was to determine the effects of soy milk consumption compared with cow's milk on inflammatory and oxidative stress markers among women with rheumatoid arthritis. Methods This randomised, cross‐over clinical trial was conducted on 25 patients (mean age: 45.72 years) with rheumatoid arthritis. Subjects were randomly assigned to two groups and were asked to follow a diet containing cow's milk or soy milk for four weeks. After the interventional period, a washout period was conducted for two weeks. Then groups followed the alternate treatment for four weeks. Results Soy milk consumption compared with cow's milk resulted in a significant difference in percent changes regarding serum levels of hs‐CRP (−13.81 ± 5.39 vs 9.21 ± 6.33%; P = 0.008) and tumour necrosis factor‐α (TNF‐α) (−15.35 ± 4.30 vs 8.11 ± 8.80%; P = 0.020). The results were not changed even after adjustment for weight. Soy milk consumption also reduced adiponectin levels significantly (baseline: 38.39 ± 2.04, end: 30.71 ± 1.93; P < 0.001). However, this reduction was not significant compared with cow's milk (P = 0.065). Soy milk consumption had no significant effects on other inflammatory factors and malondialdehyde levels. Conclusions Soy milk consumption for four weeks resulted in a significant improvement in some inflammatory markers (TNF‐α and hs‐CRP). However, further investigations are needed to confirm these effects.

Inflammation is one of the main characteristics of rheumatoid arthritis. Based on the antiinflammatory properties of sesame, this study was conducted to evaluate the sesamin supplement effects on serum levels of some proteolytic enzymes, inflammatory biomarkers, and clinical indices in women with rheumatoid arthritis. In this randomized, triple‐blind, placebo‐controlled clinical trial, 44 patients were randomly divided in intervention and control groups. Patients received 200‐mg/day sesamin supplement or placebo in the intervention and control group for 6 weeks. Serum levels of proteolytic enzymes (hyaluronidase, aggrecanase, and matrix metalloproteinases‐3) and inflammatory biomarkers (hs‐CRP, IL‐1β, IL‐6, TNF‐α, and cyclooxygenase‐2) were measured with enzyme‐linked immunosorbent assay method at the beginning and end of the study. After intervention, serum levels of hyaluronidase and matrix metalloproteinases‐3 decreased significantly in sesamin group. Also, serum levels of hs‐CRP, TNF‐α, and cyclooxygenase‐2 in intervention group were significantly decreased in intervention group compared with placebo group. Sesamin supplementation also caused a significant reduction in the number of tender joints and severity of pain in these patients. According to the results, it seems that the sesamin by reducing inflammatory mediators can relieve clinical symptoms and pathological changes that caused by inflammatory impairment in patients with rheumatoid arthritis.

The aim of this randomized, double-blind placebo-controlled trial was to determine anti-inflammatory properties of statins in rheumatoid arthritis (RA) patients.

Metformin effect on AMPK and mTOR pathways gives the capability to changes Treg/Th17 balance and decrease Th17 differentiation and inflammation, osteoclastogenesis and cancers in RA patients. Metformin can be useful in protecting bones especially in first stages of RA and it can decrease inflammation, CVD and cancer in RA patients so Metformin beside DAMARs can be useful in increasing RA patients' life quality with the less harm and cost.